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ABSTRACT 
Programmed death ligand-1 (PD-L1) is a 
critical regulator of T cell function contributing to 
peripheral immune tolerance. Although it has been 
shown that posttranscriptional regulatory 
mechanisms control PD-L1 expression in cancer, 
it remains unknown whether such regulatory loops 
operate also in non-transformed cells. Here we 
studied PD-L1 expression in human dermal 
lymphatic endothelial cells (HDLECs), which play 
key roles in immunity and cancer. Treatment of 
HDLECs with the pro-inflammatory cytokines 
IFN-γ and TNF-α synergistically upregulated PD-
L1 expression. IFN-γ and TNF-α also affected 
expression of several microRNAs (miRNAs) that 
have the potential to suppress PD-L1 expression. 
The most highly upregulated miRNA following 
IFN-γ and TNF-α treatment in HDLECs was miR-
155, which has a central role in the immune 
system and cancer. Induction of miR-155 was 
driven by TNF-α, the effect of which was 
significantly enhanced by IFN-γ. The PD-L1 3Õ-
UTR contains two functional miR-155 binding 
sites. Endogenous miR-155 controlled the kinetics 
and maximal levels of PD-L1 induction upon IFN-
γ and TNF-α treatment. We obtained similar 
findings in dermal fibroblasts, demonstrating that 
the IFN-γ/TNF-α/miR-155/PD-L1 pathway is not 
restricted to HDLECs. These results reveal miR-
155 as a critical component of an inflammation-
induced regulatory loop controlling PD-L1 
expression in primary cells.  
 
 
INTRODUCTION 
Lymphatic endothelial cells (LECs) line 
the vessels of a large network that regulate the 
traffic of immune cells and antigen to lymph 
nodes, which orchestrate the adaptive immune 
response [1]. The constant interaction between 
lymphatic vessels and the immune system enables 
the lymphatic system to serve as an important 
conduit in inflammation, infection, wound healing 
and cancer. The inflammatory response can be 
regulated by the expression of inhibitory immune 
checkpoint proteins such as programmed cell 
death protein-1 (PD-1) and its ligand PD-L1 which 
act to suppress T cell activation and induce 
peripheral tolerance [2]. Recently, immune 
restoration through PD-L1 blockade has shown 
remarkable efficacy and improvement in the 
treatment of solid cancers [3,4]. PD-L1 is widely 
expressed on immune cells including T cells, B 
cells, macrophages and dendritic cells (DCs). 
Interestingly, expression of PD-L1 has also been 
detected in murine LECs and can facilitate 
deletional or dysfunctional tolerance of CD8
+
 T 
cells [5Ð8]. However, little is known about the 
regulation of PD-L1 under an inflammatory 
environment in endothelial cells. Interferon-γ 
(IFN-γ) and tumor necrosis factor-α (TNF-α) are 
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key inducers of PD-L1 expression [9Ð11]. Of note, 
the 3Õ-untranslated region (UTR) is a crucial 
determinant of PD-L1 expression. Whole genome 
sequencing in adult patients with T cell 
leukemia/lymphoma or B cell lymphoma revealed 
structural variations that disrupted the 3Õ-UTR of 
the PD-L1 gene [12]. These variations led to 
truncation of the 3Õ-UTR resulting in elevated 
mRNA levels of PD-L1. A mouse tumor model 
with CRISPR-Cas9 deletion of the 3Õ-UTR 
confirmed an increase in PD-L1 expression 
compared to wild-type, which could be 
synergistically upregulated with IFN-γ stimulation 
[12]. This is thought to be at least partly due to the 
activity of miRNAs, which are small (20-24 nt), 
highly conserved, single-stranded non-coding 
RNAs that regulate gene expression at the 
posttranscriptional level. miRNAs regulate a wide 
range of developmental and cellular processes in 
eukaryotic organisms by directly binding to the 3Õ-
UTRs of target mRNAs to repress protein 
expression [13]. miRNAs are dysregulated in 
disease and can be used in the clinic as biomarkers 
through detection in biological fluids [14]. Studies 
have demonstrated miRNAs in the regulation of 
inflammation including miR-146a/b, miR-155 and 
miR-132 [15Ð18]. In parallel, several miRNAs, 
including miR-200, miR-34a and miR-138, have 
been found to be downregulated in cancer cells to 
allow PD-L1 expression [19Ð21]. However, it 
remains unknown whether miRNAs contribute 
towards PD-L1 regulation in human primary cells 
responding to inflammatory stimuli. 
Here we show that PD-L1 is expressed in 
primary human dermal LECs (HDLECs) and IFN-
γ and TNF-α act synergistically to induce PD-L1 
expression in these cells. Using this cellular model 
of inducible PD-L1 expression we distinguish a 
number of potential PD-L1-targeting miRNAs. We 
identify differentially regulated miRNAs upon 
IFN-γ and TNF-α stimulation of HDLECs and 
show that miR-155 is the most highly upregulated 
miRNA. Furthermore we show that there are two 
functional miR-155 binding sites on the 3Õ-UTR of 
PD-L1. Mutation of both of these binding sites 
results in de-repression of a reporter under the 
control of the PD-L1 3Õ-UTR. Consistent with 
these findings, miR-155 overexpression or 
inhibition results in suppression or enhancement of 
PD-L1 protein expression, respectively. Similar 
effects can also be observed in primary human 
dermal fibroblasts (HDFs), indicating that the 
IFN-γ/TNF-α/miR-155/PD-L1 regulatory loop is 
not restricted to HDLECs. These results suggest 
that during physiological immune activation of 
HDLECs, IFN-γ and TNF-α synergize to induce 
PD-L1 expression and concurrently activate 
miRNA networks that suppress PD-L1 expression, 
presumably to avoid prolonged immune 
suppression. Overall, our study reveals how the 
HDLEC small RNA landscape responds to 
inflammation and provides new insight into 
posttranscriptional regulation of PD-L1 in human 
primary cells.     
 
RESULTS 
PD-L1 is expressed in LECs and can be 
synergistically induced by IFN-γ and TNF-α.Ñ
Human macrovascular endothelial cells become 
activated by pro-inflammatory cytokines IFN-γ 
and TNF-α and display increased PD-L1 
expression [5,22]. However, the expression profile 
of PD-L1 in HDLECs has not been validated. PD-
L1 expression was measured at basal levels and at 
different time-points following IFN-γ and TNF-α 
stimulation. PD-L1 expression was induced after 4 
h of stimulation and this upregulation was 
increased further by 24 h (Figs. 1A and 1B). IFN-γ 
is capable of activating both signal transducer and 
activator of transcription 1 and 3 (STAT1/3). Both 
STAT1 and STAT3 have been shown to contribute 
towards increased PD-L1 expression [23,24]. In 
HDLECs, phosphorylation of STAT1 at the 
activating tyrosine residue (Y701) correlated with 
the increase of PD-L1 whereas the kinetics of 
STAT3 activation were transient but remained 
induced. Two protein bands were observed for 
PD-L1 (around 40-50 kDa). Transfection of small 
interfering RNA (siRNA) targeting PD-L1 
abolished detection of both bands (supplemental 
Fig. S1A). PD-L1 is predicted to have up to four 
N-linked glycosylation sites. De-glycosylation 
treatment led to total disappearance of both bands 
and a new band appearing at 33 kDa, which is the 
expected molecular weight of unmodified PD-L1 
(supplemental Fig. S1B). Consistently with 
induction of the JAK/STAT pathway we showed 
that PD-L1 mRNA levels were upregulated in 
activated HDLECs. IFN-γ treatment resulted in a 
ten-fold induction of PD-L1 mRNA levels at 24 h 
post-treatment (Fig. 1C). The effect was 
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significantly elevated by concurrent addition of 
TNF-α, although addition of TNF-α alone did not 
significantly affect PD-L1 mRNA levels, 
demonstrating that the effect of stimulating with 
both cytokines was synergistic. Similarly, 
increasing the concentration of IFN-γ stimulation 
led to upregulation of PD-L1 mRNA, which was 
further augmented in combination with TNF-α 
(supplemental Fig. S1C). Expression of 
interleukin-1β (IL-1β) mRNA, a downstream 
target of TNF-α signaling through the NF-κB 
pathway, was upregulated in a similar synergistic 
manner between IFN-γ and TNF-α (supplemental 
Fig. S1D). PD-L1 mRNA was measured at 8 h 
where it was strongly induced and remained at the 
same level at 24 h, consistent with the cumulative 
increase in PD-L1 protein levels (supplemental 
Fig. S1E). Although, TNF-α stimulation alone 
induced a minor increase in PD-L1 mRNA levels, 
protein expression of PD-L1 did not change 
compared to untreated (Fig. 1D). However, 
addition of TNF-α to IFN-γ-treated cells enhanced 
surface PD-L1 expression (Fig. 1E), whilst having 
minimal effects on total PD-L1 protein levels in 
comparison to treatment with IFN-γ alone (Fig. 
1D). This indicated that, in IFN-γ-treated 
HDLECs, TNF-α can affect PD-L1 localization 
and mRNA levels (Fig. 1C). The effects of IFN-γ 
and TNF-α on PD-L1 expression were also 
determined by immunofluorescence. PD-L1 was 
localized at the cell membrane and throughout the 
cytoplasm and its levels increased following 
stimulation with the cytokines (Fig. 1F). Taken 
together, these data indicated that, as in the case of 
macrovascular endothelial cells, PD-L1 is 
inducible at the transcriptional level in HDLECs 
responding to inflammatory stimuli. 
Small RNA sequencing of IFN-γ and TNF-
α-stimulated LECs reveal inflammation-
responsive miRNAsÑHaving shown that PD-L1 is 
inducible in HDLECs responding to inflammatory 
stimuli, we reasoned that this was an appropriate 
cellular model for identifying posttranscriptional 
PD-L1 regulators during inflammatory responses 
of primary human cells. To this aim and as the 
small RNA transcriptome of IFN-γ and TNF-α 
treated HDLECs had not been determined, we 
analyzed small non-coding RNAs in HDLECs 
stimulated with or without IFN-γ and TNF-α for 
24 h. Collected RNA were enriched for small 
RNAs and analyzed on an Illumina MiSeq. 
Sequencing detected small nuclear RNAs 
(snRNAs), small nucleolar RNAs (snoRNAs) and 
miRNAs (Fig. 2A). More specifically, 48 miRNAs 
were identified to be differentially regulated by 
IFN-γ and TNF-α (adjusted p < 0.1) (Fig. 2B). 
Levels of upregulated and downregulated miRNAs 
were further assessed by qRT-PCR (Fig. 2C). We 
found that IFN-γ and TNF-α resulted in 
upregulation of miR-155-5p, miR-4485-3p, miR-
218-5p and miR-146a-5p and downregulation of 
miR-582-5p, miR-582-3p, miR-93-5p, miR-217 
and miR-125b-5p (supplemental Tables S1 and 
S2). Gene ontology analysis using the miRNA 
enrichment analysis and annotation tool [25] 
indicated that predicted targets of these 
differentially regulated miRNAs were associated 
with cytokine-mediated signaling and regulation 
of inflammatory response (Fig. 2D and 
supplemental Table S3).  
miR-155 is synergistically induced by 
IFN-γ and TNF-α in HDLECsÑWe compared 
detected miRNAs from small RNA sequencing 
with miRNAs predicted to target the 3Õ-UTR of 
PD-L1 using TargetScan software [26] (Fig. 3A). 
49 detected miRNAs in basal or inflamed LECs 
also had predicted binding sites for PD-L1. 
Amongst these miRNAs, miR-155-5p (referred to 
as miR-155) was highly abundant and strongly 
induced by IFN-γ and TNF-α (Fig. 3B). As other 
highly induced miRNAs were lowly expressed we 
focused on miR-155 as a potential 
posttranscriptional regulator of PD-L1 expression 
in inflamed LECs. We dissected how miR-155 
responded to IFN-γ and TNF-α and found that 
TNF-α was the primary inducer (Fig. 3C). 
Although IFN-γ alone did not affect miR-155 
levels in HDLECs, it significantly enhanced the 
effect of TNF-α on miR-155 expression. 
Stimulating cells with increasing concentration of 
IFN-γ in conjunction with TNF-α further 
increased miR-155 expression (supplemental Fig. 
S2A). Upregulation of miR-155 by IFN-γ and 
TNF-α was observed at 8 h and continued to rise, 
remaining at high levels after 48 h (Fig. 3D). 
miR-155 regulates PD-L1 expression after 
IFN-γ and TNF-α stimulationÑWe found two 
potential miR-155 binding sites on the 3Õ-UTR of 
PD-L1 (Fig. 4A) that are conserved in human and 
mice. To determine direct regulation of PD-L1 by 
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miR-155, luciferase reporter assays were 
performed with mutagenesis of miR-155 binding 
sites. Wild-type, single or double mutated miR-
155 binding sites were co-transfected with miR-
155 mimics in HeLa cells (Fig. 4B). Mutating the 
first miR-155 binding site (Site 1) in PD-L1 3Õ-
UTR led to a significant increase in luciferase 
reporter activity compared to wild-type 3Õ-UTR, 
and the effect was more profound after mutating 
both miR-155 binding sites (Fig. 4B). Constructs 
containing the PU.1 3Õ-UTR, a previously 
validated miR-155 target [27], were used as 
controls for these assays. Next, we overexpressed 
miR-155 by transfecting miR-155 mimics into 
HDLECs (supplemental Fig. S3A). 
Overexpression of miR-155 resulted in significant 
downregulation of 24 h IFN-γ and TNF-α-induced 
PD-L1 expression (Figs. 4C and D). STAT1 
expression and phosphorylation of STAT1 were 
significantly increased (Figs. 4C and supplemental 
Fig. S3B). PD-L1 mRNA levels were consistently 
increased from overexpression of miR-155 (Fig. 
4E). 
Next, we tested whether endogenous miR-
155 could suppress PD-L1 expression. Inhibition 
of miR-155 resulted in significant upregulation of 
IFN-γ and TNF-α-induced PD-L1 expression 
(Figs. 5A and B). Suppressor of cytokine signaling 
1 (SOCS1), a published target of miR-155 [28,29] 
was noticeably increased after inhibition of miR-
155 (Fig. 5A), although there was no change upon 
overexpression of miR-155 (Fig. 4C). Expression 
of STAT1 was increased in IFN-γ and TNF-α-
stimulated cells and decreased in untreated cells 
but resulted overall in no change in 
phosphorylation of STAT1 relative to total STAT1 
(Figs. 5A and supplemental Fig. S4A). There was 
no change in the fold induction of PD-L1 mRNA 
after IFN-γ and TNF-α stimulation, compared to 
control (Fig. 5C). To determine the effect of miR-
155 on PD-L1 expression over time, we 
introduced an earlier (8 h) and later (48 h) time-
point for IFN-γ and TNF-α stimulation (Figs. 5D, 
E and supplemental Fig. S4B). Expression of PD-
L1 at all three time-points was increased following 
inhibition of miR-155 compared to control. This 
demonstrated that lack of miR-155 could affect the 
onset and maximum levels of PD-L1 expression 
upon IFN-γ and TNF-α treatment. Inhibition of 
miR-155 also resulted in the increased expression 
of SOCS1 and STAT1 that were consistently 
reproducible at the 24 h time-point, and also of 
STAT3. To determine whether miR-155 targeting 
of PD-L1 could occur in a different cell type, we 
tested our model in primary human dermal 
fibroblasts (HDFs). PD-L1 was undetectable at 
basal levels in HDFs (Fig. 6A and B). However, 
we found PD-L1 to be inducible, along with IL-1β 
and miR-155 in similar synergistic activation 
following IFN-γ and TNF-α stimulation (Figs. 6A-
C and supplemental Fig. S5A). In treated HDFs, 
miR-155 was upregulated within 8 h of 
stimulation, reaching its peak levels by 24 h (Fig. 
6D). Overexpression of miR-155 resulted in PD-
L1 downregulation in activated HDFs (Fig. 6E) 
without a statistically significant effect on PD-L1 
mRNA (Fig. 6F). Conversely, inhibition of miR-
155 led to increase of PD-L1 expression (Fig. 6G). 
miR-155 inhibition did not result in a statistically 
significant effect on PD-L1 mRNA under these 
conditions (Fig. 6H). These results indicate that 
miR-155-mediated suppression of PD-L1 is not 
specific to HDLECs and could be observed in 
other dermal primary cells responding to 
inflammatory stimuli.  
      
DISCUSSION 
We reveal that in addition to promoting 
PD-L1 expression TNF-α and IFN-γ concurrently 
lead to induction of PD-L1-targeting miRNAs 
during a physiological immune response (Fig. 7). 
We identify miR-155 as a critical 
posttranscriptional PD-L1 regulator that limits 
maximal levels of PD-L1 expression in dermal 
cells responding to inflammation, but also the 
kinetics of the PD-L1 induction. Despite its central 
role in immune responses, there is only one study 
investigating posttranscriptional regulation of PD-
L1 in non-cancer cells. miR-513 is down-regulated 
in a STAT1-dependent manner in IFN-γ-treated 
human biliary epithelial cells [30]. This is 
reminiscent of suppression of PD-L1-targeting 
miRNAs in cancer cells to allow PD-L1 
expression [19Ð21]. In contrast, our results reveal 
that inflammation-induced miRNAs are crucial 
components of regulatory loops, which control 
PD-L1 expression to avoid excessive or prolonged 
PD-L1-mediated immunosuppression. 
It is of note that miR-155, a 
multifunctional modulator of inflammation, innate 
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and adaptive immunity, suppresses PD-L1 
expression. miR-155-mediated silencing of PD-L1 
in HDLECs and HDFs were consistently observed 
at the protein but not at the mRNA level. This 
might be explained by concurrent miR-155-
mediated regulation of other genes affecting levels 
of PD-L1 mRNA (e.g. components of the 
JAK/STAT pathway) or by miR-155 primarily 
blocking PD-L1 translation rather than causing 
PD-L1 mRNA degradation. miR-155 is involved 
in development and function of T, B, and myeloid 
cells [27,31,32]. Transcribed from a highly 
conserved non-coding B-cell integration cluster 
(BIC) on chromosome 21, miR-155 is expressed in 
myeloid and lymphoid cells [32]. In several types 
of cancer, miR-155 is often abnormally expressed 
and associated with poor prognosis. As such, miR-
155 is regarded as an oncogenic miRNA in B cell 
lymphoma and several solid tumors, including 
breast, lung and colon [33Ð35]. miR-155 is 
characterized as a primary component of the 
inflammatory response whereby a broad range of 
inflammatory mediators including bacterial 
lipopolysaccharide (LPS), poly I:C and TNF-α 
activate miR-155 in human and mice 
[16,17,36,37]. Interestingly, stimulation from IFN-
β and IFN-γ also activate miR-155 and this was 
found to be dependent on TNF receptor type 1 
(TNFR1) and JNK signaling [16]. Furthermore, 
the JAK-STAT pathway is involved in 
upregulation of IFN-γ and TNF-α-induced miR-
155 expression in human retinal pigment epithelial 
cells [38]. Our findings indicate that TNF-α, a 
cytokine that is up to now associated with 
posttranslational PD-L1 stabilization [11], drives 
induction of miR-155 which suppresses PD-L1 
expression.  
The interaction between miR-155 and PD-
L1 reveals the existence of a complex regulatory 
network. SOCS1, a negative feedback regulator of 
IFN-γ/STAT signaling which inhibits JAK 
tyrosine kinase activity, has been shown to be a 
direct target of miR-155 in human and mice 
[28,29,39Ð41]. In some cases, miR-155 expression 
is inversely correlated with SOCS1, as shown in 
breast cancer [39]. Overexpression of miR-155 has 
been shown to decrease SOCS1 and increase 
phosphorylation levels of JAK2 and phospho-
STAT3 [39Ð41]. Interestingly, miR-155 
suppresses expression of SOCS1 leading to 
enhanced STAT1 phosphorylation in macrophages 
[29], miR-155-deficient CD8
+
 T cells display 
enhanced levels of STAT1 phosphorylation [42]. 
We observed that inhibition of miR-155 increased 
SOCS1 expression although overexpression of 
miR-155 did not affect SOCS1 levels in HDLECs. 
Moreover, we found no increase in STAT3 after 
miR-155 overexpression but rather an increase in 
phospho-STAT3 at 8 h after inhibiting miR-155. 
Additionally, we found that overexpression and 
inhibition of miR-155 both increased the levels of 
STAT1 indicating the existence of dose-dependent 
effects, in agreement with previous reports 
[42,43]. Based on the above, we propose that miR-
155 affects the JAK/STAT pathway through 
multiple mechanisms, likely in a cell type-specific 
manner.  Nevertheless, the observed effects of 
miR-155 mimics and inhibitors on PD-L1 protein 
expression in combination with the direct binding 
of the miRNA to the PD-L1 3Õ-UTR, demonstrate 
that direct targeting of PD-L1 by miR-155 is a 
crucial component of the cytokine receptor 
(IFNGR or TNFR)/JAK/STAT/SOCS1/miR-
155/PD-L1 network.    
Overall, our study provides a novel 
perspective on the posttranscriptional regulation of 
PD-L1 during inflammation. We reveal a number 
of potentially PD-L1-targeting miRNAs as 
responsive to inflammatory challenge. These 
include miR-155, which plays a primary role in 
inflammation and can be induced by a broad range 
of inflammatory mediators. Concomitantly, we 
show that PD-L1 is induced upon inflammation 
and contributes towards immune suppression in 
HDLECs expanding previous findings in 
macrovascular endothelial cells [5,22]. 
Furthermore we show that in dermal vascular and 
stromal cells, miR-155 acts to suppress PD-L1 
induction to fine-tune the immune response. As 
miR-155 is expressed by a variety of immune cells 
and frequently overexpressed in cancer, we 
propose that our findings have broad implications 
in our understanding of PD-L1 expression in a 
variety of physiological and disease contexts.  
 
EXPERIMENTAL PROCEDURES 
Cell culture and reagentsÑPrimary 
human dermal lymphatic endothelial cells 
(HDLEC) were purchased from Promocell and 
grown in endothelial cell growth media MV 
(Promocell) supplemented with vascular 
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endothelial growth factor C (VEGF-C) (R&D) 
[18]. All experiments with HDLEC were 
performed at passage 5. Primary human dermal 
fibroblasts (HDFs) were grown in DMEM 
supplemented with 10% FCS, 1% L-glutamine and 
1% pen/strep. Human recombinant IFN-γ was 
obtained from Peprotech and TNF-α was 
purchased from R&D.  
RNA interference and miRNA inhibitors 
and mimicsÑCells were seeded in 6-well plates 
one day before transfection with miRIDIAN hsa-
miR-155-5p mimic (25 nM), hsa-miR-155-5p 
hairpin inhibitor (50-100 nM) (GE Dharmacon) 
based on the mature hsa-miR-155-5p sequence 
(5Õ-UUAAUGCUAAUCGUGAUAGGGGU-3Õ) 
or siRNAs targeting PD-L1 (50 nM, On-
TargetPlus Smartpool, GE Dharmacon) using 
TransIT-siQuest transfection reagent (Mirus Bio). 
All experiments utilized respective negative 
controls (GE Dharmacon). 48 h posttransfection, 
cells were stimulated with IFN-γ and TNF-α for 24 
h and harvested for experimental analysis. 
RNA isolation and qRT-PCRÑTotal RNA 
was isolated using the miRNeasy Kit (Qiagen). 
PD-L1 and IL-1β mRNA expression were 
quantified by qRT-PCR using SYBR Green 
Master Mix (Applied Biosystems). β-actin was 
monitored as a housekeeping reference gene: The 
following primers were used at a final 
concentration of 300 nM: PD-L1 (F) 5Õ-
CATCTTATTATGCCTTGGTGTAGCA-3Õ; (R) 
5Õ-GGATTACGTCTCCTCCAAATGTG-3Õ; IL-
1β (F): 5Õ-AGGATGAC-
TTGTTCTTTGAAGCTGA-3Õ; (R): 5Õ-
TGCCTGAAGCCCTTGCTG-3Õ; β-actin (F) 5Õ-
CACCATTGGCAATGAGCGGTTC-3Õ, (R) 5Õ-
AGGTCTTTGCGGATGTCCACGT-3Õ. 
Commercially available primers (Applied 
Biosystems) were used to assess mature miRNA 
levels and the loading control U6 snRNA. Relative 
gene expression was calculated by the comparative 
CT method. 
Small RNA sequencingÑRNA were 
isolated and enriched for small RNA using the 
PureLink miRNA isolation kit (Ambion). RNA 
integrity was assessed using the Agilent 2100 
Bioanalyzer (Agilent Technologies). Sequencing 
libraries were generated using NEBNext Multiplex 
Small RNA Library Prep Set for Illumina (Set 1) 
(New England Biolabs) according to the 
manufacturerÕs instructions. Samples were 
sequenced using Illumina MiSeq (pair ended, 75 
bp, MiSeq v3). Sequencing reads were examined 
for quality and mapped against all annotated 
human mature and precursor miRNA sequences 
(miRBase version 21.0). Residual adapter 
sequences and indexes were removed with 
Cutadapt (version 1.8.3), in paired-end mode, first 
trimming any low-quality ends with a cutoff of 
Q10 (-q 10), then removing flanking Ns (--trim-n) 
and any reads with >20% Ns (--max-n 0.2). Reads 
were quality trimmed with Sickle (version 1.330), 
with a cutoff of >Q20 (-q 20), and truncating at the 
position of the first N (-n). Reads were mapped 
with Bowtie (version 1.0.1) with a seed length of 
15 (-l 15), a maximum total quality score at 
mismatched positions of 99999 (-e 99999), 
reporting all valid alignments per read or read pair 
(-a) and the --best option to pick the best reported 
alignments. Reads were mapped separately for 
merged reads and a concatenated file of unmerged 
forward and reverse reads. Reads were counted 
using Subread featureCounts (version 1.5.0-p1), 
with a minimum fragment length of 5 (-d 5).  
Reads were counted against all features in the 
HsGRCh38 GFF file as well as against features 
from mirBASE release 21. Counts for the mapped 
merged reads were doubled and then added to the 
counts for the mapped unmerged reads. Duplicate 
features, i.e. those with identical numbers of 
mapped reads across all samples and identical 
lengths, were removed. RPKMs (reads per 
kilobase transcript per million mapped reads) were 
calculated and then log2-transformed and 75th 
percentile-shifted. Reads mapping to protein-
coding or pseudogenes were presumed to 
correspond to degraded RNA and were excluded, 
from descriptive analyses of data (Fig. 2A). For 
each feature across all of the samples the baseline 
was set to the median value (i.e. the median 
subtracted from all of the values for that feature). 
A two-tailed t test and FDR p-value correction 
were used to assess statistical significance.  
Western blot analysisÑCells were lysed 
with ice-cold radioimmunoprecipitation assay 
(RIPA) buffer  (5 mM EDTA, 150 mM NaCl, 10 
nM Tris HCl pH 7.2, 0.1% SDS, 0.1% Triton X-
100 and 1% sodium deoxycholate) containing 
protease cocktail inhibitors P8340, P5726 and 
P0044 (Sigma). Protein concentration was 
determined by Bicinchoninic acid assay (BCA) 
(Thermo Scientific) according to the 
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manufacturerÕs protocol, using BSA as standards. 
Protein samples were denatured and resolved on 
SDS-PAGE gels using a Bio-Rad PowerPac HC 
and transferred onto PVDF membranes 
(Millipore). Membranes were probed overnight at 
4¡C (1:1000) for the following primary antibodies 
to PD-L1 (E1L3N), SOCS1 (A156), STAT1 
(9172), P-STAT1 Tyr 701 (D4A7), STAT3 
(9132), P-STAT3 Tyr 705 (D3A7) all from Cell 
Signaling, and for 1 h at room temperature for 
GAPDH (6C5) and β-actin (ab6276) both from 
Abcam. Membranes were further incubated with 
horseradish peroxidase (HRP)-conjugated 
secondary antibodies and visualized with ECL 
(GE Healthcare). Band intensity was quantified 
using ImageJ v1.50e (NIH, Bethesda, Maryland).   
PNGase F treatmentÑPeptide: N-
glycosidase F (PNGase F) was acquired from New 
England Biolabs (P0704). PNGase F was added to 
denatured protein lysates according to the 
manufacturerÕs protocol and subsequently 
analyzed by western blot.  
Luciferase assaysÑPD-L1 3Õ-UTR were 
amplified from HeLa and subcloned into the 
psiCheck2 vector using Xhol and Pmel enzymes. 
Mutations were introduced at the PD-L1 3Õ-UTR 
at the miR-155 binding site (Site1: 5Õ-
AGCAUUA-3Õ to 5Õ-UCUACAG-3Õ and Site2: 5Õ-
GCAUUAA-3Õ to 5Õ-UCUACAG-3Õ) using Q5 
site-directed mutagenesis kit (NEB) and confirmed 
by DNA sequencing. The PU.1 3Õ-UTR constructs 
were described previously [27]. Luciferase assays 
were performed in HeLa cells transfected with 
hsa-miR-155-5p mimic (50 nM) and PD-L1 or 
PU.1 3Õ-UTR constructs for 48 h using JetPrime 
reagent. Samples were assayed with the Dual-
Luciferase reporter assay system kit (Promega) for 
Firefly and Renilla luciferase activities and 
measured on a Perkin-Elmer Wallac Victor2 1420 
multi-label counter.  
Flow cytometryÑCells were incubated 
with anti-PD-L1 (5H1, kindly provided by Dr. 
Lieping ChenÕs laboratory, Yale University, USA) 
and visualized with Brilliant Violet 421 
(BioLegend) on a BD LSR Fortessa (BD 
Biosciences) using FACS DIVA software. Final 
analysis was done using FlowJo V10 (Tree Star). 
MicroscopyÑCells were cultured in 35 
mm glass-bottom dishes with a 14 mm microwell 
(MatTek). After 48 h, cells were stimulated with 
IFN-γ or in combination with TNF-α for 24 h. 
Cells were fixed in 4% paraformaldehyde and 
permeabilized with 0.5% Triton X-100. Samples 
were incubated overnight at 4¡C with anti-PD-L1 
(5H1) followed by goat anti-mouse secondary 
Alexa Fluor 488 (Thermo Scientific) and DAPI 
was used to stain the nucleus. Images were 
acquired with Zeiss Zen software using a Zeiss 
LSM 880 on a 40X oil immersion objective lens. 
Statistical analysisÑExperimental results 
are presented as mean ± S.D. The specific 
statistical tests are mentioned in the figure legends. 
Statistical analysis and graphs were made using 
GraphPad Prism 6 (GraphPad Software). 
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FOOTNOTES 
Present address (MCC) Ð Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.         
FIGURE LEGENDS 
FIGURE 1. PD-L1 is expressed in LECs and can be synergistically induced by IFN-γ and TNF-α. (A) 
Western blot analysis following a time-course of IFN-γ and TNF-α-stimulation in HDLECs. (B) Western 
blot quantification of PD-L1 expression from Fig. 1A in untreated and IFN-γ and TNF-α-treated samples, 
relative to β-actin. (C) PD-L1 mRNA levels measured by qRT-PCR after stimulation (24 h) and normal-
ized to untreated (UT). One-way analysis of variance (ANOVA) was calculated with TukeyÕs multiple 
comparisons test. **p < 0.01 and ****p < 0.0001. (D) Protein expression following titration of IFN-γ 
stimulation (24 h) with or without TNF-α. (E) Flow cytometric analysis showing PD-L1 surface expres-
sion (median fluorescence intensity) after stimulation (24 h) with IFN-γ alone (blue), or IFN-γ with TNF-
α (orange). (F) Immunofluorescence microscopy showing PD-L1 (Alexa Fluor 488) in HDLECs after 
stimulation (24 h) with IFN-γ, or in combination with TNF-α. Cells were permeabilized prior to staining. 
DAPI is shown to mark the nucleus. Scale bar = 50 µm. 
FIGURE 2. Small RNA sequencing of IFN-γ and TNF-α-stimulated LECs reveal inflammation-
responsive miRNAs. (A) Percentage distribution of sequencing results from HDLECs, showing the total 
number of hits after a threshold to filter lowly-expressed genes was applied (>50 RPKM). (B) Heat map 
showing fold change in expression of 48 miRNAs after IFN-γ and TNF-α-stimulation (24 h) in HDLECs 
(adjusted p < 0.1). Row Z-score represents standard deviations from the mean, n = 3 independent samples 
performed in triplicate. (C) Validation of selected IFN-γ and TNF-α-regulated miRNAs targets by qRT-
PCR. Statistical analysis by unpaired StudentÕs t-test, *p < 0.05, n = 3 independent samples. (D) Gene 
ontology analysis of 48 IFN-γ and TNF-α-regulated miRNAs. 
 
FIGURE 3. miR-155 is synergistically induced by IFN-γ and TNF-α. (A) Representing the overlap 
between the total number of detected miRNAs in HDLECs from small RNA-sequencing and number of 
miRNAs predicted to target PD-L1 (TargetScan). (B) Comparison of the 49 miRNAs detected in LECs 
and predicted to target PD-L1 between average expression (log10 RPKM) and change in fold expression 
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after 24 h IFN-γ and TNF-α-stimulation (log2). (C) Levels of miR-155 were measured by qRT-PCR after 
stimulation (24 h) with IFN-γ, TNF-α or both, normalized to untreated. Statistical test used was one-way 
ANOVA using TukeyÕs multiple comparisons test, n = at least 3 independent samples. (D) Time-course 
of miR-155 expression following IFN-γ and TNF-α-stimulation (8, 24 and 48 h), normalized to untreated 
(24 h), n = 3 independent samples. *p < 0.05 and ****p < 0.0001. 
 
FIGURE 4. miR-155 overexpression suppresses PD-L1 expression. (A) miR-155 has two binding sites 
on PD-L1 3Õ-UTR as predicted by TargetScan. (B) Relative Renilla luciferase (RLuc) to Firefly luciferase 
(FFLuc) activity for PD-L1 wild-type (WT) 3Õ-UTR, PD-L1 double mutant 3Õ-UTR, PD-L1 mutant 3Õ-
UTR at 1335-1341 (Site 1) and 2587-2593 (Site 2), performed in HeLa cells transfected with miR-155 
mimics (48 h). The WT and mutated 3Õ-UTR of PU.1, a known miR-155 target, was used as control. 
Statistical test used was one-way ANOVA using TukeyÕs multiple comparisons test, n = 3-4 independent 
experiments, normalized to non-targeting control (NTC). (C) Protein expression following IFN-γ and 
TNF-α stimulation (24 h) in HDLECs transfected with miR-155 mimics (48 h). (D) Western blot 
quantification of PD-L1 with miR-155 mimics, n = 3 independent experiments, normalized to untreated 
(NTC). (E) PD-L1 mRNA expression measured by qRT-PCR following IFN-γ and TNF-α stimulation (24 
h) in HDLECs transfected with miR-155 mimics (48 h), normalized to untreated (NTC). Statistical test (D 
and E) was unpaired StudentÕs t-test. *p < 0.05 and **p < 0.01, ***p < 0.001, ****p < 0.0001. 
 
FIGURE 5. Inhibition of miR-155 results in increased PD-L1 expression after IFN-γ and TNF-α 
stimulation. (A) Protein expression following IFN-γ and TNF-α stimulation (24 h) in HDLECs 
transfected with miR-155 inhibitors (48 h). (B) Western blot quantification of PD-L1 with miR-155 
inhibitors, n = 3 independent experiments, normalized to untreated (NTC). Statistical test was unpaired 
StudentÕs t-test. (C) PD-L1 mRNA fold-induction following IFN-γ and TNF-α stimulation (24 h) in 
HDLECs transfected with miR-155 inhibitors (48 h). (D) Protein expression following IFN-γ and TNF-α 
stimulation (8, 24 and 48 h) in HDLECs transfected with miR-155 inhibitors (48 h). (E) Western blot 
quantification of time-course from Fig. 5D showing expression of PD-L1 after transfection of miR-155 
inhibitors. 
 
FIGURE 6. miR-155 regulates PD-L1 in human dermal fibroblasts. (A) Western blot analysis following 
24 h stimulation of HDFs with IFN-γ and TNF-α. (B) PD-L1 mRNA levels measured by qRT-PCR after 
stimulation (24 h), normalized to untreated. One-way analysis of variance (ANOVA) was calculated with 
TukeyÕs multiple comparisons test, **p < 0.01. (C) miR-155 expression measured by qRT-PCR following 
stimulation (24 h), normalized to untreated. Statistical test used was one-way ANOVA using TukeyÕs 
multiple comparisons test. (D) Time-course of miR-155 expression following IFN-γ and TNF-α-
stimulation (8, 24 and 48 h), normalized to untreated (24 h), n = 3 independent samples. (E) Protein 
expression following IFN-γ and TNF-α stimulation (24 h) in HDFs transfected with miR-155 mimics (48 
h). (F) PD-L1 mRNA expression following IFN-γ and TNF-α stimulation (24 h) in HDLECs transfected 
with miR-155 mimics (48 h). (G) Protein expression following IFN-γ and TNF-α stimulation (24 h) in 
HDFs transfected with miR-155 inhibitors. (H) PD-L1 mRNA expression following IFN-γ and TNF-α 
stimulation (24 h) in HDLECs transfected with miR-155 inhibitors (48 h). Western blot quantification of 
PD-L1 normalized to IFN-γ and TNF-α treated NTC with standard deviation (E and G). 
 
FIGURE 7. Proposed schematic of miR-155-mediated regulation of PD-L1 in primary dermal cells 
responding to IFN-γ and TNF-α. IFN-γ and TNF-α cooperate to induce PD-L1 expression in HDLECs 
and HDFs in a synergistic manner. In parallel, the two cytokines lead to induction of miR-155, which 
suppresses PD-L1 expression through canonical miRNA/mRNA targeting. Thick arrows indicate the 
predominant cytokine driving PD-L1 or miR-155 expression. 
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Figure S1. Specific expression of PD-L1 in HDLECs. (A) Western blot analysis following 
48 h transfection of siRNA targeting PD-L1. Cells were stimulated with IFN-γ and TNF-α 
for 4, 8 and 24 h after siRNA transfection. (B) IFN-γ and TNF-α stimulated lysates were 
treated with PNGase F and analyzed by western blot. (C) qRT-PCR showing PD-L1 mRNA 
expression in cells treated with titrating amounts of IFN-γ with or without TNF-α for 24 h. 
(D) qRT-PCR measuring IL-1β levels following 24 h stimulation. (E) qRT-PCR showing 
time-course of PD-L1 mRNA expression in cells treated with IFN-γ and TNF-α for 8, 24 and 
48 h and normalized to untreated (24 h).     
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Figure S2. miR-155 expression increases with IFN-γ  dosage. (A) miR-155 was measured 
by qRT-PCR in HDLECs stimulated (24 h) with the combination of TNF-α and increasing 
ten-fold doses of IFN-γ.   
 
 
Figure S3. miR-155 overexpression affects STAT1. HDLECs were transfected with miR-
155 mimics (48 h) and treated with IFN-γ and TNF-α (24 h) (see Fig. 4C-E for context). (A) 
miR-155 levels measured by qRT-PCR. (B) Western blot quantification of STAT1 and P-
STAT1/STAT1. Statistical test was unpaired StudentÕs t-test. 
 
 
Figure S4. miR-155 inhibition affects induced STAT1 expression but not 
phosphorylation. HDLECs were transfected with miR-155 inhibitors (48 h) and treated with 
IFN-γ and TNF-α (24 h). (A) Western blot quantification of STAT1 and P-STAT1/STAT1 
(see Fig. 5A for context). Statistical test was unpaired StudentÕs t-test. (B) Western blot 
S-3 
 
quantification showing time-course expression of STAT1 and P-STAT1/STAT1 following 
IFN-γ and TNF-α stimulation for 8, 24 and 48 h (see Fig 5D).   
 
 
Figure S5. IFN-γ  and TNF-α  synergistically upregulate IL-1β in fibroblasts. (A) HDFs 
were stimulated with IFN-γ and TNF-α for 24 h and IL-1β mRNA was measured by qRT-
PCR. 
 
Table S1. Sequencing data.  
 
           
Table S2. Validation of IFN-γ  and TNF-α-regulated targets. Table showing data from 
small RNA sequencing and qRT-PCR (as shown in Fig. 2B and 2C). Values represent 
average fold change of miRNA expression following IFN-γ and TNF-α stimulation (24 h) in 
HDLECs.  
  
Table S3. miRNA enrichment analysis and annotation tool (miEAA) data. 
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